Menu Search
Equities

Malin Corporation PLC

MLC:ISE

Malin Corporation PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)5.80
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change+42.86%
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Malin Corporation PLC's net income fell -100.00% from 12.90m to 0.00 despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-0.96%
Return on equity-1.03%
Return on investment-0.96%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Malin Corporation PLC fell by 144.60m. However, Cash Flow from Investing totalled 400.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 3.20m for operations while cash used for financing totalled 141.70m.
Cash flow per share-0.0475
Price/Cash flow per share--
Book value per share6.23
Tangible book value per share6.23
More ▼

Balance sheet in EURView more

Malin Corporation PLC appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio71.80
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.